{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:33:51Z","timestamp":1793741631737,"version":"4.6.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Retrotope"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00415-022-11501-4","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T08:03:32Z","timestamp":1670054612000},"page":"1615-1623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia"],"prefix":"10.1007","volume":"270","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-214X","authenticated-orcid":false,"given":"David R.","family":"Lynch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine D.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Zesiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sub","family":"Subramony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Omidvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Krtolica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Litterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lex","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Heerinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Milner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Midei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"11501_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/ars.2009.3015","volume":"13","author":"R Santos","year":"2010","unstructured":"Santos R, Lefevre S, Sliwa D et al (2010) Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox Signal 13:651\u2013690","journal-title":"Antioxid Redox Signal"},{"key":"11501_CR2","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1096\/fj.09-143222","volume":"24","author":"JS Armstrong","year":"2010","unstructured":"Armstrong JS, Khdour O, Hecht SM (2010) Does oxidative stress contribute to the pathology of Friedreich\u2019s ataxia? A radical question. FASEB J 24:2152\u20132163","journal-title":"FASEB J"},{"key":"11501_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/14737175.2017.1356721","volume":"17","author":"C Strawser","year":"2017","unstructured":"Strawser C, Schadt K, Hauser L et al (2017) Pharmacological therapeutics in Friedreich ataxia: the present state. Expert Rev Neurother 17:895\u2013907","journal-title":"Expert Rev Neurother"},{"key":"11501_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ymgme.2007.05.009","volume":"92","author":"NE Babady","year":"2007","unstructured":"Babady NE, Carelle N, Wells RD et al (2007) Advancements in the pathophysiology of Friedreich\u2019s Ataxia and new prospects for treatments. Mol Genet Metab 92:23\u201335","journal-title":"Mol Genet Metab"},{"key":"11501_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","volume":"307","author":"AY Tsou","year":"2011","unstructured":"Tsou AY, Paulsen EK, Lagedrost SJ et al (2011) Mortality in Friedreich ataxia. J Neurol Sci 307:46\u201349","journal-title":"J Neurol Sci"},{"key":"11501_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1242\/dmm.008706","volume":"5","author":"A Martelli","year":"2012","unstructured":"Martelli A, Napierala M, Puccio H (2012) Understanding the genetic and molecular pathogenesis of Friedreich\u2019s ataxia through animal and cellular models. Dis Model Mech 5:165\u2013176","journal-title":"Dis Model Mech"},{"issue":"5","key":"11501_CR7","first-page":"130","volume":"3","author":"A Martelli","year":"2014","unstructured":"Martelli A, Puccio H (2014) Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation. Front Pharmacol 3(5):130","journal-title":"Front Pharmacol"},{"key":"11501_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0014-5793(97)00734-5","volume":"411","author":"F Foury","year":"1997","unstructured":"Foury F, Cazzalini O (1997) Deletion of the yeast homologue of the human gene associated with Friedreich\u2019s ataxia elicits iron accumulation in mitochondria. FEBS Lett 411:373\u2013377","journal-title":"FEBS Lett"},{"key":"11501_CR9","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0891-5849(99)00002-7","volume":"26","author":"SY Qian","year":"1999","unstructured":"Qian SY, Buettner GR (1999) Iron and dioxygen chemistry is an important route to initiation of biological free radical oxidations: an electron paramagnetic resonance spin trapping study. Free Radic Biol Med 26:1447\u20131456","journal-title":"Free Radic Biol Med"},{"key":"11501_CR10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3109\/10715762.2010.498477","volume":"44","author":"F Gu\u00e9raud","year":"2010","unstructured":"Gu\u00e9raud F, Atalay M, Bresgen N et al (2010) Chemistry and biochemistry of lipid peroxidation products. Free Radic Res 44:1098\u20131124","journal-title":"Free Radic Res"},{"key":"11501_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.plefa.2008.09.003","volume":"79","author":"CT Chen","year":"2008","unstructured":"Chen CT, Green JT, Orr SK, Bazinet RP (2008) Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukot Essent Fatty Acids 79:85\u201391","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"11501_CR12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.freeradbiomed.2012.06.004","volume":"53","author":"S Hill","year":"2012","unstructured":"Hill S, Lamberson CR, Xu L et al (2012) Small amounts of isotope-reinforced polyunsaturated fatty acids suppress lipid autoxidation. Free Radic Biol Med 53:893\u2013906","journal-title":"Free Radic Biol Med"},{"key":"11501_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.freeradbiomed.2010.10.690","volume":"50","author":"S Hill","year":"2011","unstructured":"Hill S, Hirano K, Shmanai VV et al (2011) Isotope-reinforced polyunsaturated fatty acids protect yeast cells from oxidative stress. Free Radic Biol Med 50:130\u2013138","journal-title":"Free Radic Biol Med"},{"key":"11501_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.redox.2013.06.004","volume":"1","author":"MG Cotticelli","year":"2013","unstructured":"Cotticelli MG, Crabbe AM, Wilson RB, Shchepinov MS (2013) Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids. Redox Biol 1:398\u2013404","journal-title":"Redox Biol"},{"key":"11501_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.phrs.2015.05.015","volume":"99","author":"R Abeti","year":"2015","unstructured":"Abeti R, Uzun E, Renganathan I et al (2015) Targeting lipid peroxidation and mitochondrial imbalance in Friedreich\u2019s ataxia. Pharmacol Res 99:344\u2013350","journal-title":"Pharmacol Res"},{"key":"11501_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.freeradbiomed.2014.12.023","volume":"82","author":"AY Andreyev","year":"2015","unstructured":"Andreyev AY, Tsui HS, Milne GL et al (2015) Isotope-reinforced polyunsaturated fatty acids protect mitochondria from oxidative stress. Free Radic Biol Med 82:63\u201372","journal-title":"Free Radic Biol Med"},{"key":"11501_CR17","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1111\/febs.14590","volume":"285","author":"A Hatami","year":"2018","unstructured":"Hatami A, Zhu C, Rela\u00f1o-Gines A et al (2018) Deuterium-reinforced linoleic acid lowers lipid peroxidation and mitigates cognitive impairment in the Q140 knock in mouse model of Huntington\u2019s disease. FEBS J 285:3002\u20133012","journal-title":"FEBS J"},{"key":"11501_CR18","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1111\/febs.14291","volume":"284","author":"A Elharram","year":"2017","unstructured":"Elharram A, Czegledy NM, Golod M et al (2017) Deuterium-reinforced polyunsaturated fatty acids improve cognition in a mouse model of sporadic Alzheimer\u2019s disease. FEBS J 284:4083\u20134095","journal-title":"FEBS J"},{"key":"11501_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.toxlet.2011.07.020","volume":"207","author":"MS Shchepinov","year":"2011","unstructured":"Shchepinov MS, Chou VP, Pollock E et al (2011) Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson\u2019s disease. Toxicol Lett 207:97\u2013103","journal-title":"Toxicol Lett"},{"key":"11501_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/21678421.2018.1549531","volume":"20","author":"R Bedlack","year":"2019","unstructured":"Bedlack R (2019) ALS Untangled No. 47: RT001. Amyotroph Lateral Scler Frontotemporal Degener 20:294\u2013297","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"11501_CR21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/antiox10071021","volume":"10","author":"PR Angelova","year":"2021","unstructured":"Angelova PR, Andruska KM, Midei MG et al (2021) RT001 in progressive supranuclear palsy-clinical and in-vitro observations. Antioxidants (Basel) 10:1021","journal-title":"Antioxidants (Basel)"},{"key":"11501_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/jmd2.12116","volume":"54","author":"D Adams","year":"2020","unstructured":"Adams D, Midei M, Dastgir J et al (2020) Treatment of infantile neuroaxonal dystrophy with RT001: a di-deuterated ethyl ester of linoleic acid: Report of two cases. JIMD Rep 54:54\u201360","journal-title":"JIMD Rep"},{"key":"11501_CR23","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/mds.27353","volume":"33","author":"T Zesiewicz","year":"2018","unstructured":"Zesiewicz T, Heerinckx F, De Jager R et al (2018) Randomized, clinical trial of RT001: early signals of efficacy in Friedreich\u2019s ataxia. Mov Disord 33:1000\u20131005","journal-title":"Mov Disord"},{"key":"11501_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/acn3.660","volume":"6","author":"DR Lynch","year":"2018","unstructured":"Lynch DR, Farmer J, Hauser L et al (2018) Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol 6:15\u201326","journal-title":"Ann Clin Transl Neurol"},{"key":"11501_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Chin MP, Delatycki MB et al (2021) Safety and efficacy of omaveloxolone in Friedreich Ataxia (MOXIe Study). Ann Neurol 89:212\u2013225","journal-title":"Ann Neurol"},{"key":"11501_CR26","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.apmr.2010.04.007","volume":"91","author":"BE Drinkard","year":"2010","unstructured":"Drinkard BE, Keyser RE, Paul SM et al (2010) Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia. Arch Phys Med Rehabil 91:1044\u20131050","journal-title":"Arch Phys Med Rehabil"},{"key":"11501_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1212\/NXG.0000000000000371","volume":"5","author":"C Rummey","year":"2019","unstructured":"Rummey C, Corben LA, Delatycki MB et al (2019) Psychometric properties of the Friedreich Ataxia Rating Scale. Neurol Genet 5:371","journal-title":"Neurol Genet"},{"key":"11501_CR28","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/acn3.332","volume":"3","author":"M Patel","year":"2016","unstructured":"Patel M, Isaacs CJ, Seyer L et al (2016) Progression of Friedreich ataxia: quantitative characterization over 5 years. Ann Clin Transl Neurol 3:684\u2013694","journal-title":"Ann Clin Transl Neurol"},{"key":"11501_CR29","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mds.22912","volume":"25","author":"LS Friedman","year":"2010","unstructured":"Friedman LS, Farmer JM, Perlman S et al (2010) Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord 25:426\u2013432","journal-title":"Mov Disord"},{"key":"11501_CR30","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1212\/01.wnl.0000218155.46739.90","volume":"66","author":"DR Lynch","year":"2006","unstructured":"Lynch DR, Farmer JM, Tsou AY et al (2006) Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology 66:1711\u20131716","journal-title":"Neurology"},{"key":"11501_CR31","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/01.WNL.0000156802.15466.79","volume":"64","author":"SH Subramony","year":"2005","unstructured":"Subramony SH, May W, Lynch D et al (2005) Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64:1261\u20131262","journal-title":"Neurology"},{"key":"11501_CR32","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1023\/A:1025014509626","volume":"12","author":"JS Lai","year":"2003","unstructured":"Lai JS, Cella D, Chang CH et al (2003) Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale. Qual Life Res 12:485\u2013501","journal-title":"Qual Life Res"},{"key":"11501_CR33","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1016\/j.xphs.2020.08.019","volume":"109","author":"JT Brenna","year":"2020","unstructured":"Brenna JT, James G, Midei M et al (2020) Plasma and red blood cell membrane accretion and pharmacokinetics of RT001 (bis-Allylic 11,11-D2-Linoleic Acid Ethyl Ester) during Long Term Dosing in Patients. J Pharm Sci 109:3496\u20133503","journal-title":"J Pharm Sci"},{"key":"11501_CR34","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.4155\/bio.15.118","volume":"7","author":"AJ Worth","year":"2015","unstructured":"Worth AJ, Basu SS, Deutsch EC et al (2015) Stable isotopes and LC-MS for monitoring metabolic disturbances in Friedreich\u2019s ataxia platelets. Bioanalysis 7:1843\u20131855","journal-title":"Bioanalysis"},{"key":"11501_CR35","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/mds.22038","volume":"23","author":"LM Myers","year":"2008","unstructured":"Myers LM, Lynch DR, Farmer JM et al (2008) Urinary isoprostanes in Friedreich ataxia: lack of correlation with disease features. Mov Disord 23:1920\u20131922","journal-title":"Mov Disord"},{"key":"11501_CR36","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1212\/WNL.55.11.1719","volume":"55","author":"JB Schulz","year":"2000","unstructured":"Schulz JB, Dehmer T, Sch\u00f6ls L et al (2000) Oxidative stress in patients with Friedreich ataxia. Neurology 55:1719\u20131721","journal-title":"Neurology"},{"key":"11501_CR37","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","volume":"6","author":"NA Di Prospero","year":"2007","unstructured":"Di Prospero NA, Baker A, Jeffries N, Fischbeck KH (2007) Neurological effects of high-dose idebenone in patients with Friedreich\u2019s ataxia: a randomised, placebo-controlled trial. Lancet Neurol 6:878\u2013886","journal-title":"Lancet Neurol"},{"key":"11501_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.88207","volume":"1","author":"C DeBrosse","year":"2016","unstructured":"DeBrosse C, Nanga RPR, Wilson N et al (2016) Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders. JCI Insight 1:e88207","journal-title":"JCI Insight"},{"key":"11501_CR39","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.30054","volume":"6","author":"V Chandran","year":"2017","unstructured":"Chandran V, Gao K, Swarup V et al (2017) Inducible and reversible phenotypes in a novel mouse model of Friedreich\u2019s Ataxia. Elife 6:e30054","journal-title":"Elife"},{"key":"11501_CR40","doi-asserted-by":"publisher","first-page":"15788","DOI":"10.1038\/s41598-020-72884-w","volume":"10","author":"L Weng","year":"2020","unstructured":"Weng L, Laboureur L, Wang Q et al (2020) Extra-mitochondrial mouse frataxin and its implications for mouse models of Friedreich\u2019s ataxia. Sci Rep 10:15788","journal-title":"Sci Rep"},{"key":"11501_CR41","doi-asserted-by":"publisher","first-page":"17043","DOI":"10.1038\/s41598-018-35346-y","volume":"8","author":"L Guo","year":"2018","unstructured":"Guo L, Wang Q, Weng L et al (2018) Characterization of a new N-terminally acetylated extra-mitochondrial isoform of frataxin in human erythrocytes. Sci Rep 8:17043","journal-title":"Sci Rep"},{"key":"11501_CR42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/eurjpc\/zwaa134","volume":"29","author":"C Pane","year":"2022","unstructured":"Pane C, Salzano A, Trinchillo A et al (2022) Safety and feasibility of upper limb cardiopulmonary exercise test in Friedreich ataxia. Eur J Prev Cardiol 29:445\u2013451","journal-title":"Eur J Prev Cardiol"},{"key":"11501_CR43","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.apmr.2010.04.007","volume":"91","author":"BE Drinkard","year":"2010","unstructured":"Drinkard BE, Keyser RE, Paul SM, Arena R, Plehn JF, Yanovski JA, Di Prospero NA (2010) Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia. Arch Phys Med Rehabil 91:1044\u20131050","journal-title":"Arch Phys Med Rehabil"},{"key":"11501_CR44","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0960-8966(00)00108-5","volume":"10","author":"M Vorgerd","year":"2000","unstructured":"Vorgerd M, Sch\u00f6ls L, Hardt C, Ristow M, Epplen JT, Zange J (2000) Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscul Disord 10:430\u2013435","journal-title":"Neuromuscul Disord"},{"key":"11501_CR45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1474-4422(21)00027-2","volume":"20","author":"K Reetz","year":"2021","unstructured":"Reetz K, Dogan I, Hilgers R-D et al (2021) Progression characteristics of the European Friedreich\u2019s\u00a0Ataxia\u00a0Consortium for Translational Studies (EFACTS): a 4-year cohort study. Lancet Neurol 20:362\u2013372","journal-title":"Lancet Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11501-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11501-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11501-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T13:08:13Z","timestamp":1677503293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11501-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["11501"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11501-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]},"assertion":[{"value":"29 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"IRB approval was obtained by the Institutional Review Board at each Institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all subjects before initiation of study procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}